The first time I believed ACT was on the brink of worldwide acclaim lured ahead of the first approval and subsequent injections. The second time I rejoiced prior to the Lancet, which continued on throughout the 2012 ASM time period.
My visceral objections were subsided by thoughts of clinical celerity. Looking back, ACT was nothing more than a babushka doll fashioned as a paragon of the biotech industry.
Here I was, still anticipating hysteria at any moment. With
Many of us know that Asia has a high prevalence of MMD for unknown reasons. The numbers are staggering with up to 80% of all people-- specifically in China and Singapore. The prevalence of severe myopia too, is skyrocketing.
I believe that ACT is determined to tap into this market. My guess is not China(we could go on all day about why that would be), but instead Singapore!!
Of course, we put together many threads after Lanza made a keynote speech at the 4th annual stem
So satisfying to hear Gary withdraw ACT from the conventional cell therapy approaches. NO, this company is not comparable to any of the names you have mentioned, and we are targeting indications that are on a much larger scale. ACT stands alone and Gary has made that very clear.
This strategic plan is a big deal. Obviously augmenting the management team of the company with plans to commercialize these projects was one of the components of this plan. Getting on the NASDAQ,
Gary did a really great job recently in his attempt to identify the differentiating factors that encompass ACT. At what point, however, does this "Event-Driven" company define its long-term strategic planning?
In saying that, I mean at what point does ACT grow a spine and produce a trade name for MA-09RPE?
at what point, does Gary introduce ACT's strategic planning--for more than one year at a time?
Common questions a company must ask itself:
This was going to be a post but got way too off topic and started to get personal, so I'll just blog it?
horrible conference if you ask me. most of what i heard i either found annoying or frustrating. I can't believe all these scientists can be so polarized. I can feel the frustration in Vincent's tone by the end, Rabin was rushing throughout the entire presentation...and Im not sure that a lot of people were able to grasp the differences from a manufacturing, efficacy/potency,